Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0FJCZS)
| ADC Name |
AMG 172
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
AMG 172
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen (Top20 MNC) (Originator);Amgen (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD70 mAb
|
Antibody Info | ||||
| Antigen Name |
CD70 antigen (CD70)
|
Antigen Info | ||||
| Payload Name |
DM1
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
emtansine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
2027 Update
General Information of The ADMET Data Related to This ADC
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Clearance (CL) | 9.45 | mL/h |
AMG 172 CL was estimated to be 9.45 mL/hr in a typical human (70 kg) based on species-invariant time scaling methods.
|
[1] |
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | stable disease (SD) |
16.20%
|
|||
| Patients Enrolled |
Eligible subjects require clear cell RCC refractory to ≥2 prior therapies (including a TKI) with measurable disease (RECIST 1.1), ECOG ≤1, adequate hematologic (ANC ≥1.5x10<sup>9</sup>/L, platelets ≥100x10<sup>9</sup>/L) and hepatic function (AST/ALT <3xULN). Exclusions encompass CNS metastases, bleeding disorders, significant cardiac comorbidities (recent MI, CHF NYHA >II, QTcF >470ms), uncontrolled HTN, or active HBV/HCV/HIV infections.
Click to Show/Hide
|
||||
| Administration Dosage |
The study was conducted in two parts for dose exploration and dose expansion on a biweekly dosing schedule. AMG 172 doses of 0.15, 0.3, 0.6, 1.2, 1.6, 1.8, and 2.4 mg/kg were studied in the dose-exploration phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01497821 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 172 in Subjects With Relapsed / Refractory Renal Cell Carcinoma | ||||
| Primary Endpoint |
Primary safety assessments include ≥Grade 3 CTCAE adverse events and clinically significant lab/ECG changes monitored for 28 days post-enrollment. Pharmacokinetic parameters (Cmax, AUC, t½) are evaluated across 12 timepoints within 8 weeks. The MTD will be determined for two dosing schedules (biweekly/triweekly) with tumor response (RECIST 1.1) assessed over 3 years.
Click to Show/Hide
|
||||
| Other Endpoint |
Secondary endpoints include immunogenicity (anti-drug antibodies over 1 year), non-MTD cohort ORR (RECIST 1.1), and clinical benefit via DOR, all evaluated through 3 years.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | progressive disease (PD) |
35.10%
|
|||
| Patients Enrolled |
Eligible subjects require clear cell RCC refractory to ≥2 prior therapies (including a TKI) with measurable disease (RECIST 1.1), ECOG ≤1, adequate hematologic (ANC ≥1.5x10<sup>9</sup>/L, platelets ≥100x10<sup>9</sup>/L) and hepatic function (AST/ALT <3xULN). Exclusions encompass CNS metastases, bleeding disorders, significant cardiac comorbidities (recent MI, CHF NYHA >II, QTcF >470ms), uncontrolled HTN, or active HBV/HCV/HIV infections.
Click to Show/Hide
|
||||
| Administration Dosage |
The study was conducted in two parts for dose exploration and dose expansion on a biweekly dosing schedule. AMG 172 doses of 0.15, 0.3, 0.6, 1.2, 1.6, 1.8, and 2.4 mg/kg were studied in the dose-exploration phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01497821 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 172 in Subjects With Relapsed / Refractory Renal Cell Carcinoma | ||||
| Primary Endpoint |
Primary safety assessments include ≥Grade 3 CTCAE adverse events and clinically significant lab/ECG changes monitored for 28 days post-enrollment. Pharmacokinetic parameters (Cmax, AUC, t½) are evaluated across 12 timepoints within 8 weeks. The MTD will be determined for two dosing schedules (biweekly/triweekly) with tumor response (RECIST 1.1) assessed over 3 years.
Click to Show/Hide
|
||||
| Other Endpoint |
Secondary endpoints include immunogenicity (anti-drug antibodies over 1 year), non-MTD cohort ORR (RECIST 1.1), and clinical benefit via DOR, all evaluated through 3 years.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Partial Response (PR) |
5.40%
|
|||
| Patients Enrolled |
Eligible subjects require clear cell RCC refractory to ≥2 prior therapies (including a TKI) with measurable disease (RECIST 1.1), ECOG ≤1, adequate hematologic (ANC ≥1.5x10<sup>9</sup>/L, platelets ≥100x10<sup>9</sup>/L) and hepatic function (AST/ALT <3xULN). Exclusions encompass CNS metastases, bleeding disorders, significant cardiac comorbidities (recent MI, CHF NYHA >II, QTcF >470ms), uncontrolled HTN, or active HBV/HCV/HIV infections.
Click to Show/Hide
|
||||
| Administration Dosage |
The study was conducted in two parts for dose exploration and dose expansion on a biweekly dosing schedule. AMG 172 doses of 0.15, 0.3, 0.6, 1.2, 1.6, 1.8, and 2.4 mg/kg were studied in the dose-exploration phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01497821 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 172 in Subjects With Relapsed / Refractory Renal Cell Carcinoma | ||||
| Primary Endpoint |
Primary safety assessments include ≥Grade 3 CTCAE adverse events and clinically significant lab/ECG changes monitored for 28 days post-enrollment. Pharmacokinetic parameters (Cmax, AUC, t½) are evaluated across 12 timepoints within 8 weeks. The MTD will be determined for two dosing schedules (biweekly/triweekly) with tumor response (RECIST 1.1) assessed over 3 years.
Click to Show/Hide
|
||||
| Other Endpoint |
Secondary endpoints include immunogenicity (anti-drug antibodies over 1 year), non-MTD cohort ORR (RECIST 1.1), and clinical benefit via DOR, all evaluated through 3 years.
|
||||
References